

CLAIMS

1. ~~Use of an~~ anti-CD38 antibody in the manufacture of a medicament for ~~use in~~ treating ~~an multiple myeloma in a human~~ individual ~~in need thereof~~, wherein at least a first, a second, and a third intravenous infusion of the anti-CD38 antibody is to be administered to the individual, wherein the anti-CD38 antibody is to be administered at a dose of ~~at least 10 mg/kg, wherein the dose of the anti-CD38 antibody is in a volume of 250 ml, and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).~~ 10 mg/kg, wherein the dose of the anti-CD38 antibody is in a volume of 250 ml.
2. ~~Use of an anti-CD38 antibody in the manufacture of a medicament for treating multiple myeloma in a human individual, wherein at least a first intravenous infusion of the anti-CD38 antibody is to be administered to the individual, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg, wherein the dose of the anti-CD38 antibody is in a volume of 250 ml, and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).~~
3. ~~The anti-CD38 antibody for use according to claim 1 or the use of claim 2 wherein the anti-CD38 antibody is isatuximab.~~
4. ~~The anti-CD38 antibody for use according to claim 1 or 3 wherein the anti-CD38 antibody is for the treatment of a disease or disorder, optionally wherein the disease or disorder is multiple myeloma.~~
5. ~~The anti-CD38 antibody for use of any one of claims 1 and 3-4 or the use of any one of claims 2-3, wherein the first intravenous infusion of the anti-CD38 antibody is to be~~ wherein the

first intravenous infusion of the anti-CD38 antibody is to be administered to the individual at an infusion rate of 25 mL/hour for a first hour, and wherein the infusion rate is increased by 25 mL/hour every 30 minutes after the first hour to a maximum infusion rate of 150 mL/hour until the 250 ml volume is infused-₂

6. ~~_____ The anti-CD38 antibody for use of any one of claims 1 and 3-4 or the use of any one of claims 2-3, wherein the first infusion of the anti-CD38 antibody is to be administered to the individual at an infusion rate of 12.5 mL/hour for a first 30 minutes, and wherein the infusion rate is increased by 25 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.~~

7. ~~_____ The anti-CD38 antibody for use according to any one of claims 1 and 3-6, or the use of any one of claims 2-3 and 5-6, at least a second intravenous infusion of the anti-CD38 antibody is to be administered to the individual, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg in a volume of 250 ml.~~

8. ~~_____ The anti-CD38 antibody for use or the use of claim 7, wherein the second intravenous infusion of the anti-CD38 is to be _____ wherein the second intravenous infusion of anti-CD38 antibody is to be~~ administered to the individual at an infusion rate of 50 mL/hour for a first 30 minutes, wherein the infusion rate is increased by 50 mL/hour a second 30 minutes, and wherein the infusion rate is increased by 100 mL/hour every 30 minutes after the second 30 minutes to a maximum infusion rate of 200 mL/hour until the 250 ml volume is infused-₂

9. ~~_____ The anti-CD38 antibody for use or the use of claim 7, _____ wherein the secondthird intravenous infusion of the anti-CD38 antibody is to be administered to the individual at an infusion rate of 50 mL200 ml/hour for a first 30 minutes, 100 mL/hour for a second 30 minutes, 200 mL for the third 30 minutes, and 300 mL/hour after the third 30 minutes until the 250 ml volume is infused-₂ and~~

10. ~~_____ The anti-CD38 antibody for use or the use of claim 7, wherein the second intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 25 mL/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.~~

11. ~~_____ wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain~~

variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).

2. The ~~anti-CD38 antibody for use or the use of any one of claims 7-10,~~claim 1 wherein ~~at least a third intravenous infusion of the anti-CD38 antibody is to be administered to the individual, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg in a volume of 250 ml~~isatuximab.

~~12. The anti-CD38 antibody for use or the use of claim 11, wherein the third intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 200 ml/hour until the 250 ml volume is infused.~~

~~13. The anti-CD38 antibody for use or the use of claim 11, wherein the third intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.~~

~~14. The anti-CD38 antibody for use or the use of any one of claims 11-13.~~ The use of claim 1 or 2, comprising a fourth intravenous infusion of the anti-CD38 antibody ~~that~~ is to be administered to the individual, wherein the anti-CD38 antibody is to be administered at a dose of ~~at least~~ 10 mg/kg in a volume of 250 ml.

~~154.~~ The ~~anti-CD38 antibody for use or the use of claim 143,~~ wherein the fourth intravenous infusion of the anti-CD38 antibody is to be administered to the individual at an infusion rate of 200 ml/hour until the 250 ml volume infused.

~~165.~~ The ~~anti-CD38 antibody for use or the use of claim 143,~~ wherein the fourth intravenous infusion of the anti-CD38 antibody is to be administered to the individual at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.

~~176.~~ The ~~anti-CD38 antibody for use or the use of any one of claims 14-163-5,~~ wherein the anti-CD38 antibody is to be administered in a first 28-day cycle, wherein the first intravenous infusion of the anti-CD38 antibody is to be administered on Day 1, the second intravenous infusion of the anti-CD38 antibody is to be administered on Day 8, the third intravenous infusion of the anti-CD38 antibody is to be administered on Day 15, and the fourth intravenous infusion of the anti-CD38

antibody is to be administered on Day 22 the first 28-day cycle.

~~187.~~ The ~~anti-CD38 antibody for use or the~~ use of any one of claims ~~14-173-6~~, wherein one or more subsequent intravenous infusions of the anti-CD38 antibody are to be administered to the individual following the fourth intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of ~~at least~~ 10 mg/kg in a volume of 250 ml for each of the one or more subsequent intravenous infusions.

~~198.~~ The ~~anti-CD38 antibody for use or the~~ use of claim ~~187~~, wherein each of the one or more subsequent intravenous infusions of the anti-CD38 antibody following the fourth intravenous infusion is to be administered to the individual at an infusion rate of 200 ml/hour until the 250 ml volume infused.

~~209.~~ The ~~anti-CD38 antibody for use or the~~ use of claim ~~187~~, wherein each of the one or more subsequent intravenous infusions of the anti-CD38 antibody following the fourth intravenous infusion is to be administered to the individual at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.

~~2110.~~ The ~~anti-CD38 antibody for use or the~~ use of any one of claims ~~18-207-9~~, wherein the anti-CD38 antibody is to be administered in one or more subsequent 28-day cycles following the first 28-day cycle, wherein each of the one or more subsequent intravenous infusions of the anti-CD38 antibody following the fourth intravenous infusion is to be administered on Days 1 and 15 of each of the one or more subsequent 28-day cycles following the first 28-day cycle.

~~22.~~ ~~An~~ ~~11.~~ Use of an anti-CD38 antibody in the manufacture of a medicament for ~~use in~~ treating ~~an multiple myeloma in a human~~ individual ~~in need thereof~~, wherein at least three intravenous infusions of the anti-CD38 antibody are to be administered to the individual, wherein the anti-CD38 antibody is to be administered at a dose of ~~at least~~ 10 mg/kg, wherein the dose of the anti-CD38 antibody is in a volume of 250 ml, and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6) ~~);~~ ;

wherein the first intravenous infusion of the anti-CD38 antibody is to be administered to the individual at an infusion rate of 25 mL/hour for a first hour, and wherein the infusion rate is increased by 25 mL/hour every 30 minutes after the first hour to a maximum infusion rate of 150 mL/hour until the 250 ml volume is infused;

wherein the second intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 50 mL/hour for a first 30 minutes, wherein the infusion rate is increased by 50 ml/hr a second 30 minutes, and wherein the infusion rate is increased by 100 mL/hour every 30 minutes after the second 30 minutes to a maximum infusion rate of 200 mL/hour until the 250 ml volume is infused; and

wherein the third intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.

~~23. ——— Use of an anti-CD38 antibody in the manufacture of a medicament for treating multiple myeloma in a human individual, wherein at least three intravenous infusion of the anti-CD38 antibody is to be administered to the individual, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg, wherein the dose of the anti-CD38 antibody is in a volume of 250 ml, and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6);~~

~~——— wherein the first intravenous infusion of the anti-CD38 antibody is to be administered to the individual at an infusion rate of 25 mL/hour for a first hour, and wherein the infusion rate is increased by 25 mL/hour every 30 minutes after the first hour to a maximum infusion rate of 150 mL/hour until the 250 ml volume is infused;~~

~~——— wherein the second intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 50 mL/hour for a first 30 minutes, wherein the infusion rate is increased by 50 ml/hr a second 30 minutes, and wherein the infusion rate is increased by 100 mL/hour every 30 minutes after the second 30 minutes to a maximum infusion rate of 200 mL/hour until the 250 ml volume is infused; and~~

~~——— wherein the third intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.~~

~~24~~12. The ~~anti-CD38 antibody for use according to~~claim 22 or the use of claim 23~~11~~, wherein the anti-CD38 antibody is isatuximab.

~~25~~13. The ~~anti-CD38 antibody for use according to claim 22 or 24 wherein the anti-CD38 antibody is for the treatment of a disease or disorder, optionally wherein the disease or disorder is multiple myeloma.~~

~~26~~—. The anti-CD38 antibody for use according to ~~any one of claims 21 and 23-25, or the use of any one of claims 22-24~~use of claim 11 or 12, wherein one or more subsequent intravenous infusions of the anti-CD38 antibody are to be administered following the third intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of ~~at least~~ 10 mg/kg in a volume of 250 ml for each of the one or more subsequent intravenous infusions.

~~27~~14. The ~~anti-CD38 antibody for use or the use of claim 26~~13, wherein each of the one or more subsequent intravenous infusions of the anti-CD38 antibody following the third intravenous infusion is to be administered to the individual at an infusion rate of 200 ml/hour until the 250 ml volume infused.

~~28~~—. ~~An anti-CD38 antibody for use in treating an individual in need thereof, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg, wherein the volume of each dose of the anti-CD38 antibody is 250 ml, and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).~~

~~29~~15. Use of an anti-CD38 antibody in the manufacture of a medicament for treating multiple myeloma in an individual, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion comprising at least a first, a second, and a third intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of ~~at least~~ 10 mg/kg, wherein the volume of ~~each~~ dose of the anti-CD38 antibody is 250 ml, ~~and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR H1 comprising the amino acid sequence~~

DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).

wherein the first intravenous infusion of the anti-CD38 antibody is to be administered to the individual at an infusion rate of 25 mL/hour for a first hour, and wherein the infusion rate is increased by 25 mL/hour every 30 minutes after the first hour to a maximum infusion rate of 150 mL/hour until the 250 ml volume is infused,

wherein the second intravenous infusion of anti-CD38 antibody is to be administered to the individual at an infusion rate of 50 mL/hour for a first 30 minutes, wherein the infusion rate is increased by 50 mL/hour a second 30 minutes, and wherein the infusion rate is increased by 100 mL/hour every 30 minutes after the second 30 minutes to a maximum infusion rate of 200 mL/hour until the 250 ml volume is infused,

wherein the third intravenous infusion of the anti-CD38 antibody is to be administered to the individual at an infusion rate of 200 mL/hour until the 250 ml volume is infused, and

wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).

16. The anti-CD38 antibody for use according to claim 28 or the use of claim 29, wherein the anti-CD38 antibody is isatuximab.

31. The anti-CD38 antibody for use according to claim 28 or 30 wherein the anti-CD38 antibody is for the treatment of a disease or disorder, optionally wherein the disease or disorder is multiple myeloma.

32. The anti-CD38 antibody for use according to any one of claims 28 and 30-31, or the use of any one of claims 29-30, wherein the anti-CD38 antibody is to be administered in a first 28-day cycle, and wherein the anti-CD38 antibody is to be administered on

Days 1, 8, 15, and 22 of the first 28-day cycle.

[3318](#). The ~~anti-CD38 antibody for use or the~~ use of claim [3217](#), wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 1 of the first 28 day cycle at an infusion rate of 25 mL/hour for a first hour, and wherein the infusion rate is increased by 25 mL/hour every 30 minutes after the first hour to a maximum infusion rate of 150 mL/hour until the 250 ml dose of the anti-CD38 antibody is infused.

[3419](#). The ~~anti-CD38 antibody for use or the~~ use of claim [3217](#), wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 1 of the first 28 day cycle at an infusion rate of 12.5 mL/hour for a first 30 minutes, and wherein the infusion rate is increased by 25 mL/hour every 30 minutes after the first 30 minutes until the 250 ml dose of the anti-CD38 antibody is infused.

[3520](#). The ~~anti-CD38 antibody for use or the~~ use of any one of claims [32-3417-19](#), wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 8 of the first 28 day cycle at an infusion rate of 50 mL/hour for a first 30 minutes, wherein the infusion rate is increased by 50 ml/hr for an second 30 minutes, and wherein the infusion rate is increased by 100 mL/hour every 30 minutes after the second 30 minutes to a maximum infusion rate of 200 mL/hour until the 250 ml volume is infused.

[3621](#). The ~~anti-CD38 antibody for use or the~~ use of any one of claims [32-3417-19](#), wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 8 of the first 28 day cycle at an infusion rate of 50 mL/hour for a first 30 minutes, 100 mL/hour for a second 30 minutes, 200 mL for the third 30 minutes, and 300 mL/hour after the third 30 minutes until the 250 ml dose of the anti-CD38 antibody is infused.

[3722](#). The ~~anti-CD38 antibody for use or the~~ use of any one of claims [32-3417-19](#), wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 8 of the first 28 day cycle at an infusion rate of 25 mL/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml dose of the anti-CD38 antibody is infused.

[3823](#). The ~~anti-CD38 antibody for use or the~~ use of any one of claims [32-3717-22](#), wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 15 of the first 28-day cycle at an infusion rate of 200 ml/hour until the 250 ml dose of the anti-CD38 antibody is infused.

[3924](#). The ~~anti-CD38 antibody for use or the~~ use of any one of claims [32-3717-22](#), wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 15 of the first 28 day cycle at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml dose of the anti-CD38 antibody is infused.

[4025](#). The ~~anti-CD38 antibody for use or the~~ use of any one of claims [32-3917-24](#), wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 22 of the first 28-day cycle at an infusion rate of 200 ml/hour until the 250 ml dose of the anti-CD38 antibody is infused.

[4126](#). The ~~anti-CD38 antibody for use or the~~ use of any one of claims [32-3917-24](#), wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 22 of the first 28 day cycle at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml dose of the anti-CD38 antibody is infused.

[4227](#). The ~~anti-CD38 antibody for use or the~~ use of any one of claims [32-4117-26](#), wherein the anti-CD38 antibody is to be further administered in one or more subsequent 28-day cycles, and wherein the anti-CD38 antibody is to be administered at a dose of ~~at least~~ 10 mg/kg on Days 1 and 15 of each subsequent 28 day cycle, wherein the volume of each dose of the anti-CD38 antibody to be administered in the one or more subsequent cycles is 250 ml.

[4328](#). The ~~anti-CD38 antibody for use or the~~ use of claim [4227](#), wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 1 of each subsequent 28-day cycle at an infusion rate of 200 ml/hour until the 250 ml dose of the anti-CD38 antibody is infused.

[4429](#). The ~~anti-CD38 antibody for use or the~~ use of claim [4227](#), wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 1 of each subsequent 28-day cycle at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml dose of the anti-CD38 antibody is infused.

[4530](#). The ~~anti-CD38 antibody for use or the~~ use of any one of claims [42-4427-29](#), wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 15 of each subsequent 28-day cycle at an infusion rate of 200 ml/hour until the 250 ml dose of the anti-CD38

antibody is infused.

[4631](#). The ~~anti-CD38 antibody for use or the~~ use of any one of claims [42-44](#)~~27-29~~, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 15 of each subsequent 28 day cycle at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml dose of the anti-CD38 antibody is infused.

~~47. — An~~ [32](#). Use of an anti-CD38 antibody [in the manufacture of a medicament](#) for ~~use in~~ treating ~~an multiple myeloma in a human~~ individual ~~in need thereof~~, wherein at least a first dose of the anti-CD38 antibody is to be ~~safely~~ administered to the individual via intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of ~~at least~~ 10 mg/kg in a volume of 250 ml, wherein the first dose is infused over a duration ~~of about~~[between](#) 1.5 and ~~about~~ 6.5 hours, and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).

~~48. — Use of an anti-CD38 antibody in the manufacture of a medicament for treating multiple myeloma in a human individual, wherein at least a first dose of the anti-CD38 antibody is to be administered to the individual via intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg in a volume of 250 ml, wherein the first dose is infused over a duration of about 1.5 and about 6.5 hours, and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).~~

[4933](#). The ~~anti-CD38 antibody for use~~ ~~according to~~ claim [47](#) ~~or the use of claim~~ [48](#)~~32~~, wherein the anti-CD38 antibody is isatuximab.

~~5034.~~ The ~~anti-CD38 antibody for use according to claim 47 or 49, wherein the anti-CD38 antibody is for the treatment of a disease or disorder, optionally wherein the disease or disorder is multiple myeloma.~~

~~51.~~—The ~~anti-CD38 antibody for use according to any one of claims 47 and 49-50, or the use of any one of claims 48-49~~use of claim 32 or 33, wherein at least a second dose of the anti-CD38 antibody is to be administered to the individual via intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of ~~at least~~ 10 mg/kg in a volume of 250 ml, wherein the second dose is infused over a duration ~~of about~~between 0.5 and 3.5 hours.

~~5235.~~ The ~~anti-CD38 antibody for use according to any one of claims 41 and 43-45, or the use of any one of claims 42-45~~27-30, wherein at least a third dose of the anti-CD38 antibody is to be administered to the individual via intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of ~~at least~~ 10 mg/kg in a volume of 250 ml, wherein the third dose is infused over a duration ~~of about~~between 0.5 and 1.5 hours.

~~5336.~~ The ~~anti-CD38 antibody for use according to~~of any one of claims ~~1, 3-22, 24-28, 30-47, and 49-52, or the use of any one of claims 2-3, 5-21, 23-24, 26-27, 29-30, 32-46, 48-49, and 51-52-35~~, wherein the administration of the anti-CD38 antibody does not result in the individual experiencing an infusion reaction (IR).

~~5437.~~ The ~~anti-CD38 antibody for use according to~~of any one of claims ~~1, 3-22, 24-28, 30-47, and 49-52, or the use of any one of claims 2-3, 5-21, 23-24, 26-27, 29-30, 32-46, 48-49, and 51-52-35~~, wherein the administration of the anti-CD38 antibody does not result in the individual experiencing an IR greater than Grade 1 in severity.

~~5538.~~ The ~~anti-CD38 antibody for use according to any one of 1, 3-22, 24-28, 30-47, and 49-52, or the use of any one of claims 2-3, 5-21, 23-24, 26-27, 29-30, 32-46, 48-49, and 51-52-35~~, wherein the administration of the anti-CD38 antibody does not result in the individual experiencing an IR of Grade 2 or greater in severity.

~~5639.~~ The ~~anti-CD38 antibody for use according to any one of claims 1, 3-22, 24-28, 30-47, and 49-55, or the use of any one of claims 2-3, 5-21, 23-24, 26-27, 29-30, 32-46, 48-49, and 51-55~~ 1-38, wherein the ~~at least~~ 10 mg/kg dose of the anti-CD38 antibody in the volume of 250 ml further comprises 0.9% sodium chloride or 5% dextrose.

~~5740.~~ The ~~anti-CD38 antibody for use according to any one of claims 1, 3-22, 24-28, 30-47, and 49-~~

~~56, or the use of any one of claims 2-3, 5-21, 23-24, 26-27, 29-30, 32-46, 48-49, and 51-561-39,~~
wherein the individual does not receive premedication with one or more of an analgesic, an antacid,
an anti-inflammatory agent, an antihistamine prior for the purpose of preventing or minimizing an
infusion reaction prior to the administration of the anti-CD38 antibody via intravenous infusion.

~~5841. The anti-CD38 antibody for use according to of any one of claims 1, 3-22, 24-28, 30-47,~~
~~and 49-57, or the use of any one of claims 2-3, 5-21, 23-24, 26-27, 29-30, 32-46, 48-49, and 51-57,~~
~~wherein the dose of anti-CD38 antibody is 10 mg/kg or 20 mg/kg.~~

~~59. An anti-CD38 antibody for use in treating multiple myeloma in an individual, wherein an~~
~~anti-CD38 antibody comprises (a) a heavy chain variable domain (V_H) that comprises: a CDR-H1~~
~~comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino~~
~~acid sequence TIYPGDCGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino~~
~~acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (V_L) that~~
~~comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a~~
~~CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3~~
~~comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6), pomalidomide, and~~
~~dexamethasone;~~

~~wherein the anti-CD38 antibody is to be administered in 28 day cycles;~~

~~wherein the anti-CD38 antibody is to be administered on Days 1, 8, 15, and 22 of a first~~
~~28 day cycle;~~

~~wherein the anti-CD38 antibody is to be administered on Days 1 and 15 of every 28 day~~
~~cycle following the first 28 day cycle;~~

~~and wherein the anti-CD38 antibody is to be administered at a dose of 10 mg/kg or 20~~
~~mg/kg.~~

~~60. Use of an anti-CD38 antibody comprising (a) a heavy chain variable domain (V_H) that~~
~~comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2~~
~~comprising the amino acid sequence TIYPGDCGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3~~
~~comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain~~
~~variable domain (V_L) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA~~
~~(SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO:~~
~~5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6);~~
~~pomalidomide, and dexamethasone, in the manufacture of a medicament for treating multiple~~
~~myeloma in a human individual;~~

~~wherein the anti-CD38 antibody is to be administered in 28 day cycles;~~

_____ wherein the anti-CD38 antibody is to be administered on Days 1, 8, 15, and 22 of a first 28-day cycle;

_____ wherein the anti-CD38 antibody is to be administered on Days 1 and 15 of every 28-day cycle following the first 28-day cycle;

_____ and wherein the anti-CD38 antibody is to be administered at a dose of 10 mg/kg or 20 mg/kg.

61. _____ The anti-CD38 antibody for use according to claim 59 or the use of claim 60, wherein the individual has at least one high-risk cytogenetic abnormality selected from: 17p deletion, 4(4;14) translocation, and t(14;16) translocation.

62. _____ The anti-CD38 antibody for use or the use of claim 61, wherein the individual has at least two high-risk cytogenetic abnormalities.

63. _____ The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-62 or the use of any one of claims 5-21, 26-27, 32-46, and 51-62-40, wherein the multiple myeloma is relapsed/refractory multiple myeloma.

64-42. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-63 or the use of any one of claims 5-21, 26-27, 32-46, and 51-63-41, wherein the individual was refractory to the most recent prior therapy for multiple myeloma.

65-43. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-64 or the use of any one of claims 5-21, 26-27, 32-46, and 51-64-42, wherein the individual is refractory to lenalidomide.

66-44. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-65 or the use of any one of claims 5-21, 26-27, 32-46, and 51-65-43, wherein the most recent prior therapy was lenalidomide.

67-45. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-66 or the use of any one of claims 5-21, 26-27, 32-46, and 51-66-44, wherein the individual is refractory to a proteasome inhibitor.

68-46. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-67 or the use of any one of claims 5-21, 26-27, 32-46, and 51-67-45, wherein the most recent prior therapy was a proteasome inhibitor.

[6947](#). The ~~anti-CD38 antibody for use or the~~ use of claim [6745](#) or [6846](#), wherein the proteasome inhibitor is selected from the group consisting of: bortezomib, carfilzomib, marizomib, oprozomib, and ixazomib.

[7048](#). The ~~anti-CD38 antibody for use or the~~ use of any one of claims ~~64-69~~[42-47](#), wherein the lenalidomide and the proteasome inhibitor were administered in combination.

[7149](#). The ~~anti-CD38 antibody for use according to of~~ any one of claims ~~1, 3-22, 24-28, 30-47, and 49-70, or the use of any one of claims 2-3, 5-21, 23-24, 26-27, 29-30, 32-46, 48-49, and 51-70,~~ wherein the individual has a respiratory disorder, thoracic disorder, and/or mediastinal disorder.

[7250](#). The ~~anti-CD38 antibody for use or~~ use of claim [7149](#), wherein the respiratory disorder is chronic obstructive pulmonary disorder (COPD).

[7351](#). The ~~anti-CD38 antibody for use or~~ use of claim [7149](#), wherein the respiratory disorder is asthma.

[7452](#). The ~~anti-CD38 antibody for use or~~ use of claim [7149](#), wherein the respiratory disorder is bronchospasm.

[7553](#). The ~~anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-74 or the use of any one of claims 5-21, 26-27, 32-46, and 51-74~~[1-52](#), wherein the individual has received at least two prior therapies for multiple myeloma.

[7654](#). The ~~anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-75 or the use of any one of claims 5-21, 26-27, 32-46, and 51-75~~[1-53](#), wherein the individual has received at least three prior therapies for multiple myeloma.

[7755](#). The ~~anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-76 or the use of any one of claims 5-21, 26-27, 32-46, and 51-76~~[1-54](#), wherein the anti-CD38 antibody is to be administered in conjunction with at least one additional agent.

[7856](#). The ~~anti-CD38 antibody for use or the~~ use of claim [7755](#), wherein the at least one additional agent comprises an immunomodulatory drug.

[7957](#). The ~~anti-CD38 antibody for use or the use of~~ claim [7856](#), wherein the immunomodulatory

drug is lenalidomide or pomalidomide.

~~8058.~~ The ~~anti-CD38 antibody for use of any one of claims 4-21, 25-27, 3-10, 13-14, 17-31-46, and 50-79 or the use of any one of claims 5-21, 26-27, 32-46, and 51-79~~34-57, wherein the at least one additional agent comprises a proteasome inhibitor.

~~8159.~~ The ~~anti-CD38 antibody for use or the use of claim 8058~~, wherein the proteasome inhibitor is bortezomib, carfilzomib, marizomib, oprozomib, and ixazomib.

~~82.~~ ~~The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-81 or the~~60.
The use of any one of claims 5-21, 26-27, 32-46, and 51-81, wherein the at least one additional agent comprises a corticosteroid.

~~8361.~~ The ~~anti-CD38 antibody for use or the use of~~ claim 8260, wherein the corticosteroid is dexamethasone.

~~84.~~ ~~A kit comprising isatuximab for treating an individual having multiple myeloma according to the use of any one of claims 5-21, 26-27, 32-46, and 51-83.~~

~~85.~~ ~~An intravenous bag containing between about 360 mg and 1600 mg of an anti-CD38 antibody in a volume of 250 ml, wherein the wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).~~